Medtronic MDT Diabetes — Reportable segment operating profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's diabetes — reportable segment operating profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's diabetes — reportable segment operating profit?
- Medtronic (MDT) reported diabetes — reportable segment operating profit of $57M in Q4 2025.
- How has Medtronic's diabetes — reportable segment operating profit changed year-over-year?
- Medtronic's diabetes — reportable segment operating profit increased by 14.0% year-over-year, from $50M to $57M.
- What is the long-term trend for Medtronic's diabetes — reportable segment operating profit?
- Over 3 years (2022 to 2025), Medtronic's diabetes — reportable segment operating profit has grown at a -5.9% compound annual growth rate (CAGR), from $589M to $490M.
- What does diabetes — reportable segment operating profit mean?
- The profit earned by the diabetes segment from its core operations before corporate overhead and taxes.
- How do you interpret diabetes — reportable segment operating profit?
- An increase indicates improved operational efficiency or higher margins, while a decrease suggests rising costs or pricing pressure.
- How does diabetes — reportable segment operating profit compare across companies?
- Standard operating profit metric for business segments in diversified corporations.